beth israel deaconess medical center a harvard medical school teaching hospital

  • Contact BIDMC
  • Maps & Directions
  • Other Locations
  • Careers at BIDMC
  • Smaller Larger

Find a Doctor

Request an Appointment

Smaller Larger

Aspirin may Reduce Recurrence Risk

Posted 4/28/2016

Posted in

  There have been a number of studies suggesting that daily low dose aspirin, especially for people ages 50-59, may reduce the risk of cardiovascular disease and colorectal cancers. There are always caveats, and the recommendation is always to discuss it with your doctor.

A newly released study from Cardiff University suggests that daily low dose aspirin may reduce the recurrence rate of some cancers by up to 20%. Again there is the caveat about talking first with your doctor as daily aspirin does increase the incidence of internal bleeding. There are some medical conditions that preclude aspirin's use for that reason. This does seem worth consideration and a conversation.

  From MedScape comes this summary:

Aspirin 'Helps Cancer Survival After Treatment
Tim Locke

Taking low-dose aspirin after cancer treatment can help improve survival by up to 20%, according to a Cardiff University's School of Medicine analysis.
Although other studies have suggested aspirin has cancer-fighting properties, regular aspirin use can cause internal bleeding, so experts say people thinking of taking it should talk to their doctor first.
Looking at the Evidence
The findings don't come from a new trial, but instead researchers analysed data from 47 good quality studies on aspirin and breast cancer, bowel cancer and prostate cancer, with participants followed-up for an average of 5 years. Some studies compared aspirin with a dummy (placebo) treatment, while others observed aspirin use in people treated for cancer.
The timing of starting aspirin treatment varied across the studies analysed.
They found evidence that aspirin can help reduce cancer deaths, and stop cancers spreading. However, deeper research would be needed to find out whether it is more effective with certain types of tumour, or cancers linked to specific genetic markers.
The research is published in the journal PLOS ONE.

Read more:


Add your comment